AI Article Synopsis
Article Abstract
Background: Emerging evidence of antibody-independent functions, as well as the clinical efficacy of anti-CD20 depleting therapies, helped to reassess the contribution of B cells during multiple sclerosis (MS) pathogenesis.
Objective: To investigate whether CD19 B cells may share expression of the serine-protease granzyme-B (GzmB), resembling classical cytotoxic CD8 T lymphocytes, in the peripheral blood from relapsing-remitting MS (RRMS) patients.
Methods: In this study, 104 RRMS patients during different treatments and 58 healthy donors were included. CD8, CD19, Runx3, and GzmB expression was assessed by flow cytometry analyses.
Results: RRMS patients during fingolimod (FTY) and natalizumab (NTZ) treatment showed increased percentage of circulating CD8GzmB T lymphocytes when compared to healthy volunteers. An increase in circulating CD19GzmB B cells was observed in RRMS patients during FTY and NTZ therapies when compared to glatiramer (GA), untreated RRMS patients, and healthy donors but not when compared to interferon-β (IFN). Moreover, regarding Runx3, the transcriptional factor classically associated with cytotoxicity in CD8 T lymphocytes, the expression of GzmB was significantly higher in CD19Runx3-expressing B cells when compared to CD19Runx3 counterparts in RRMS patients.
Conclusions: CD19 B cells may exhibit cytotoxic behavior resembling CD8 T lymphocytes in MS patients during different treatments. In the future, monitoring "cytotoxic" subsets might become an accessible marker for investigating MS pathophysiology and even for the development of new therapeutic interventions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859463 | PMC |
| http://dx.doi.org/10.3389/fimmu.2022.750660 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Alopecia Universalis in a Multiple Sclerosis Patient After Switching From Rituximab to Ocrelizumab: A Case Report.
Int J Rheum Dis
December 2024
Department of Neurology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ocrelizumab is a humanized monoclonal antibody, which acts as an anti-CD20 antibody. It is used as a treatment of both relapsing-remitting multiple sclerosis (RRMS) and Progressive types. The aim of this study is to report the first patient with alopecia universalis after switching from rituximab to ocrelizumab.
View Article and Find Full Text PDFThe impact of bladder symptoms on Relapsing Remitting Multiple Sclerosis patients' Quality of Life - a pilot study.
Wiad Lek
December 2024
DEPARTMENT OF NEUROLOGY, FACULTY OF MEDICAL SCIENCES IN KATOWICE, MEDICAL UNIVERSITY OF SILESIA, KATOWICE, POLAND.
Objective: Aim: Bladder disorders are one of the most troubling symptoms of Multiple Sclerosis (MS), which impact patients quality of life (QoL). Therefore the aim of this pilot study was to assess this problem.
Patients And Methods: Materials and Methods: 47 patients (28 females and 19 males, aged 40,8±12,2 years; EDSS 3,2±1,9) diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS) during disease modifying treatment (DMT) were enrolled to our study.
Longitudinal trajectories of digital upper limb biomarkers for multiple sclerosis.
Eur J Neurol
January 2025
Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Background: Upper limb dysfunction is a common debilitating feature of relapsing-remitting multiple sclerosis (RRMS). We aimed to examine the longitudinal trajectory of the iPad®-based Manual Dexterity Test (MDT) and predictors of change over time.
Methods: We prospectively enrolled RRMS patients (limited to Expanded Disability Status Scale (EDSS) < 4).
[Effectiveness and tolerance of azathioprine as first-line treatment for multiple sclerosis: a case study from Morocco].
Pan Afr Med J
December 2024
Laboratoire de Biologie et Santé, Faculté des Sciences, Université Ibn-Tofail, Kenitra, Maroc.
Introduction: the purpose of our study is to evaluate the efficacy of azathioprine as first-line treatment in patients with relapsing-remitting multiple sclerosis (RRMS) or progressive multiple sclerosis (PMS), who were supposed to be treated with beta-interferons but, due to limited resources, received azathioprine instead.
Method: among the 31 patients, 17 had relapsing-remitting MS (RRMS), 11 had primary progressive MS (PPMS), and 3 had secondary progressive MS (SPMS). Patients received azathioprine orally at a dose of 3 mg/kg/day over 2 years.
Investigating the complementary value of OCT to MRI in cognitive impairment in relapsing-remitting multiple sclerosis.
Mult Scler
December 2024
Queen Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
Background: Cognitive decline in multiple sclerosis (MS) is associated with neuro-axonal loss, quantifiable by optical coherence tomography (OCT). Associations between OCT measures and cognition in relapsing-remitting MS (RRMS) remain incompletely investigated, particularly the added value of OCT when combined with magnetic resonance imaging (MRI). We investigated the contributions of OCT and MRI while applying stringent criteria to control for subclinical optic neuropathy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!